Biomedical International R+D GmbH

Profile

  • RDM* biotech/pharma
  • Founded in: 2008
  • Staff: 0
  • Indications:
    Neoplasms
    Diseases of the respiratory system
  • Topic: Human health
  • Cluster Membership: LISAvienna
  • R&D: 1.) Allergy is an increasing burden of mankind and pets with prevalences of up to 40%. The only causative treatment is systemic immunotherapy (SIT) using allergen extracts which are injected into the patient in order to induce tolerance.By entrapping the allergen into biodegradable PLGA microspheres it is protected from degradatio. Simultaneously local side effects are prevented. To achieve specific attachment to immune uptake sites, the microparticles are decorated with a specific lectin - Alaurea aurantia lectin (AAL). AAL is derived from an edible mushroom and specifically binds to M-cells of tonsils and so-called Peyers patches in the intestine. This leads to enhanced efficacy and lower risk for local side effects. 2.) Cancer is a health threat with a great demand of novel, improved therapies. In cancer, immunotherapy is today mostly performed in a passive mode, by supplying the patientsĀ“ blood with immunoglobulins against specific molecules on cancer cells. In contrast to these passiveimmunotherapies, we aim to actively stimulate the patientĀ“s immune system to build up own protective antibodies. The principle of vaccination against infectious diseases is well known. Also prophylaxis for high-risk patients can be envisaged.The overexpression of the HER-2 molecule in 1/7 breast cancer patients is associated with bad prognosis. The new vaccine is based on HER-2 mimotopes displayed by Adeno-associated virus particles. Moreover, several other tumor types express HER-2 and may thus be also targeted by the Biomed vaccine. 3.) Biomed develops biometric methods for the improvement of PoC studies.
  • Services: Research and preclinical Development. Partnering with universities.

Contact